Quinoline Derivatives Inhibit BRD4 Bromodomain Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases mediated by bromodomain-containing protein 4 (BRD4) lack effective inhibitors and modulators, which are necessary to address aberrant gene expression and various pathological conditions such as cancer, diabetes, and inflammatory disorders.
Innovation Solution
Development of specific chemical compounds, including those of Formula IC, which can inhibit or modulate BRD4 activity, formulated into pharmaceutical compositions for administration in treating diseases responsive to BRD4 inhibition, such as cancer and inflammatory disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for diseases mediated by BRD4, then existing therapeutic approaches are maintained, but effective inhibition of BRD4 is not achieved
Solution Approach 1:
The patent introduces small molecule compounds as intermediaries that bind to the bromodomain of BRD4, blocking its interaction with acetylated histones. These compounds act as mediators between the therapeutic need and the molecular target, effectively inhibiting BRD4-mediated gene expression without directly modifying the protein structure
Solution Approach 2:
The invention modifies chemical parameters by developing compounds with specific structural features ( Formula I with defined substituents R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, R43, R44, R45, R46, R47, R48, R49, R50, R51, R52, R53, R54, R55, R56, R57, R58, R59, R60, R61, R62, R63, R64, R65, R66, R67, R68, R69, R70, R71, R72, R73, R74, R75, R76, R77, R78, R79, R80, R81, R82, R83, R84, R85, R86, R87, R88, R89, R90, R91, R92, R93, R94, R95, R96, R97, R98, R99, R100) that optimize binding affinity and selectivity for BRD4, thereby changing the chemical parameters to achieve effective inhibition
2Adaptability or versatility
If no specific BRD4 inhibitors are available, then existing drug regimens continue, but diseases responsive to BRD4 inhibition cannot be effectively treated
Solution Approach 1:
The patent develops a universal platform of compounds (Formula I and Formula II) that can inhibit multiple BET family members (BRD2, BRD3, BRD4, BRDT) while maintaining disease-specific efficacy. This multi-functional approach allows a single compound class to address various diseases mediated by different BET proteins, expanding treatment coverage across cancer, inflammatory disorders, and other conditions
Data Source
AI summary
This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula I, wherein R, R2, R3, R4, R7, W, X are as described herein and Z is selected from the group consisting of unsubstituted or substituted isoxazolyl, and unsubstituted or substituted pyrazolyl. Provided herein are also methods for the preparation and use of the compounds, and to pharmaceutical compositions containing the same.